- Changes to the Board of Directors
- Evolution of the organization and leadership appointment
Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960) announces today changes to its board of directors and management structure, a new step in the implementation of its strategic roadmap announced in March 2020.
Board of Directors
As Voluntis continues to simplify its organization in line with its strategic roadmap, the Board of Directors has approved a reduction in its size. In conjunction with this evolution, Roberta Herman and Nicolas Cartier have resigned as members of the Board of Directors due to each of them taking on new leadership roles: Dr Herman as President and CEO of Joslin Diabetes Center and Mr. Cartier as COO of Merieux NutriSciences. This revised Board structure, with six directors of which two are independent, became effective July 30, 2020.
“On behalf of my fellow directors, the company’s management team, and shareholders, I’d like to thank Roberta and Nicolas for the significant contributions they made during their years of service on the Voluntis Board,” said Eric Elliott, Voluntis’ Chairman. “While we will miss the benefit of their contribution, moving forward, a reduced size of our Board is consistent with our decision to adopt a leaner company governance.”
Organization and leadership team
In parallel, the Company organization has been simplified to sustain competitiveness and promote innovation and talents, whilst assuring continuity in the Company’s skills, culture and values.
The Executive Committee and the Global Management Committee are now merged into a single Management Committee, led by the Chief Executive Officer, Pierre Leurent. All commercial activities are now regrouped under a single unit, headed by Romain Marmot, appointed Chief Business Officer.
As a result of the organizational changes, the Chief Operations Officer role has been removed and Alexandre Capet, former COO in Europe, is leaving the company to pursue other interests.
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.